Femasys (FEMY) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Femasys (FEMY) has outperformed Fractyl Health (GUTS) over the past year, losing 93.3% versus a loss of 95.1%. Fractyl Health is the larger company by market cap ($10.9 million vs $10.7 million), about 1.0 times the size, while Femasys is growing revenue faster (+40.8% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FEMY | GUTS |
|---|---|---|
| Share price | $1.24 | $0.82 |
| Market cap | $10.73M | $10.88M |
| 1-day change | 0.00% | -14.16% |
| YTD return | -89.24% | -96.89% |
| 1-year return | -93.26% | -95.12% |
| 5-year return | -98.63% | — |
| EPS (TTM) | $-1.79 | $-3.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.29M | $0 |
| Revenue growth (YoY) | +40.77% | -100.00% |
| Net income (latest FY) | $-18.63M | $-140.95M |
| Gross margin | 61.96% | — |
| Operating margin | -766.95% | — |
| Net margin | -812.27% | — |
| 52-week high | $20.80 | $29.34 |
| 52-week low | $1.07 | $0.784 |
| Distance from 52-week high | -94.04% | -97.21% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1055.65% | +7265.85% |
| Average volume | 110.75K | 504.39K |
| Shares outstanding | 8.66M | 13.26M |
| Employees | 51 | 100 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Femasys grew revenue faster in its latest fiscal year (+40.77% vs -100.00%).
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
FEMY vs GUTS FAQ
Which is bigger, Femasys or Fractyl Health?
Fractyl Health (GUTS) is larger, with a market capitalization of $10.88M compared with $10.73M for Femasys (FEMY).
Which stock has performed better over the past year, FEMY or GUTS?
FEMY returned -93.26% over the past 12 months, compared with -95.12% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Femasys and Fractyl Health in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.